Scarica l'app Stockscreener
11.54
14.42%
-1.945
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SLS Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$13.49
Aprire:
$13.55
Volume 24 ore:
14.56M
Relative Volume:
1.78
Capitalizzazione di mercato:
$2.33B
Reddito:
-
Utile/perdita netta:
$-29.46M
Rapporto P/E:
-50.57
EPS:
-0.2283
Flusso di cassa netto:
$-28.17M
1 W Prestazione:
-16.70%
1M Prestazione:
+4.48%
6M Prestazione:
+110.68%
1 anno Prestazione:
+510.85%
Intervallo 1D:
$11.38
$13.74
Intervallo di 1 settimana:
$11.38
$14.37
Portata 52W:
$1.39
$15.88
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
Nome
Sellas Life Sciences Group Inc
Settore
Industria
Telefono
(646) 200-5278
Indirizzo
7 TIMES SQUARE, NEW YORK, NY
Compare SLS vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
11.54 | 2.33B | 0 | -29.46M | -28.17M | -0.2283 |
VRTX
Vertex Pharmaceuticals Inc
|
515.44 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
781.49 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.39 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
143.97 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.77 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-07-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-11-01 | Iniziato | Oppenheimer | Outperform |
| 2018-04-02 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-19 | Aggiornamento | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc Borsa (SLS) Ultime notizie
SLS Stock July Rout Deepens: ‘Pharma Bro’ Martin Shkreli Questions Timing Of AML Trial, Says Data May Wait Until Christmas - Stocktwits
SLS Stock Jumps Overnight: ‘Potent’ AML Drug Data Ahead Of Cancer Summit Fuels Fresh Momentum - Stocktwits
SLS Stock Jumps Premarket: CEO Says GPS AML Data Has ‘Very Good Chance’ To Beat Earlier Survival Outcomes - Stocktwits
SLS Stock Pops Big After Hours On Imminent Leukemia Trial Data Readout Optimism - Stocktwits
SLS Stock Rises Overnight: Traders Rally Behind Jim Cramer's 'Two Thumbs Up' Call Ahead Of Key AML Readout - Stocktwits
SLS Stock Snaps 2-Day Slide: Sellas’ SLS009 AML Trial Spotlights Big Pharma Drug Combo From ABBV, RHHBY And BMY - Stocktwits
SLS Stock Extends Rally Overnight: CEO Says ‘Bullish’ Leukemia Data Could Drive NCCN Recognition For GPS - Stocktwits
Life Sciences Companies Present Live at the September 17 Virtual Investor Forum - Yahoo Finance
10 Health Care Stocks With Whale Alerts In Today’s Session - Benzinga
SLS Stock Hits 4-Year High: BlackRock Stake Boost Fuels Buzz Around Looming AML Trial Readout - Stocktwits
SELLAS Life Sciences Group, Inc. (SLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
SLS Stock Rises Overnight: Why Retail Traders Prefer Sellas Over IBRX, ONDS, PYPL As Most Bullish Pick - Stocktwits
SLS CEO Angelos Stergiou Highlights Extended Capital Runway To Pursue Key Milestones, Growth Opportunities – A Look At The Important Numbers - Stocktwits
SELLAS Life Sciences Group, Inc. • Robinhood Token (SLS) Price Prediction for 2026 to 2031 - Bybit
SLS Stock Tests $5 Again: Retail Targets ‘No’ Vote On 20M Share Dilution Push Before AML Trial Results - Stocktwits
Investigation launched into Sellas Life Sciences over delayed clinical trial results and stock drop - Pluang
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc.SLS - PR Newswire
Why Did SLS, BB, OUST Stocks Surge To 52-Week Highs Today? - Stocktwits
SLS Stock Hits Over 5-Year High: Retail Traders Bet Big On Breaking $25 As AML Readout Looms - Stocktwits
SLS Stock Rises Overnight: Retail Traders Call New AML Survival Data 'Huge' Ahead Of CEO’s Fox Appearance - Stocktwits
SLS Stock Clocks Three Straight Weeks Of Gains On Cancer Vaccine Spillover, REGAL Trial Data Anticipation - Stocktwits
SLS Stock Edges Higher As Wall Street, Retail Expect Another MRNA Moment - Stocktwits
SLS Stock Logs Record H1 As AML Trial Nears Finish Line — Why Are Retail Traders Refusing To Cash Out? - Stocktwits
Sellas Life Sciences Draws Significant Retail Buzz As Traders Eye REGAL Phase 3 Catalyst – SLS Stock Soars 15% - Stocktwits
Why Did SLS, MRNA, ABCL Stocks Surge To 52-Week Highs Last Week? - Stocktwits
SLS Short Interest Hits All-Time High: Sellas Bulls Smell A Short Squeeze As Executive Contract Changes Fuel Buyout Chatter - Stocktwits
Bronstein, Gewirtz & Grossman, LLC Encourages SELLAS Life Sciences Group, Inc. (SLS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages SELLAS Life Science - The National Law Review
Sellas’ Experimental Drug SLS009 Appears To Be Leading The CDK9 Race, Says Alliance Global – Analyst Sees About 200% Upside Potential - Stocktwits
SLS Stock Sparks Retail Buzz Ahead of AACR Presentation On Experimental Cancer Therapy - Stocktwits
SLS Stock Rises Overnight: Healthcare Execs Tout AML Drug As ‘Game Changer’ Ahead Of Final Trial Trigger - Stocktwits
SELLAS Life Sciences Group, Inc. (SLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
SLS Stock Pops After-Hours As Loss Shrinks, Cash Swells — All Eyes On High Stakes AML Trial In 'Pivotal' 2026 - Stocktwits
SLS, IBRX Eye Green Month As Biotech ETF Gains Steam: Analyst Sees ‘Continued Opportunities’ In Immuno-Oncology - Stocktwits
SLS Stock Gains Momentum: NVDA, MSFT Investor Loads Up Ahead Of AML Trial Milestone Trigger - Stocktwits
SLS Stock Slides Premarket: Traders Brace For Key Arbitration Ruling In GPS China Payment Dispute - Stocktwits
SLS Stock Tanks Hard: Retail Traders Blame Warrant Holders, 'Flippers' Cashing Out Before AML Catalyst - Stocktwits
SLS Stock Takes A Breather After Big Run: Traders Eye AML Summit Featuring Advisor For Clues On Trial Readout - Stocktwits
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against SELLAS Life Sciences Group, Inc. (SLS) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
SELLAS Life Sciences Group (SLS) Lands 3 AACR Abstracts For SLS009 Pancreatic Cancer Data - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against SELLAS Life Sciences Group, Inc. (SLS) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Sellas Gears Up To Present Preclinical SLS009 Data For Pancreatic Cancer At Major Oncology Conference - Yahoo Finance
Sellas Life Sciences Group Inc Azioni (SLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.24%
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):